Lead Product(s) : Opaganib
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Preclinical
Sponsor : Duke University School
Deal Size : Undisclosed
Deal Type : Collaboration
RedHill Collaborates with U.S. Academic Center on Opaganib for Phosgene Injury
Details : The collaboration is designed to test ABC294640 (opaganib), a first-in-class, orally administered SPHK2 selective inhibitor, as a potential medical countermeasure to treat phosgene inhalation injury.
Product Name : Yeliva
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 22, 2024
Lead Product(s) : Opaganib
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Preclinical
Sponsor : Duke University School
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mycapssa® (octreotide capsules) is approved in the US for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa® is the first and only oral somatostatin analog approve...
Product Name : Mycapssa
Product Type : Peptide
Upfront Cash : Inapplicable
July 14, 2022
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Preclinical
Sponsor : Jubilant Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Collaboration aims to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the context of COVID-19 related cytokine storms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Preclinical
Sponsor : Jubilant Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Human Ipsc-Derived Cardiac Tissues
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Preclinical
Sponsor : National Institutes of Health
Deal Size : $4.6 million
Deal Type : Funding
NanoSurface Biomedical Awarded $1.9M in Funding from NIH
Details : The SBIR funding will be used to develop NanoSurface’s innovative platform for modeling and assessing human cardiac function on-a-chip.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 03, 2020
Lead Product(s) : Human Ipsc-Derived Cardiac Tissues
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Preclinical
Sponsor : National Institutes of Health
Deal Size : $4.6 million
Deal Type : Funding
Lead Product(s) : Ruxolitinib Phosphate
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Preclinical
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Novartis, Incyte to test Jakavi for coronavirus-linked cytokine storm
Details : Novartis plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi for treatment of severe immune overreaction called cytokine storm in COVID-19.
Product Name : Jakavi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 04, 2020
Lead Product(s) : Ruxolitinib Phosphate
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Preclinical
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Collaboration